DBV Technologies Proudly Welcomes Dr. Lucia Septien as Chief Medical Officer
July 05, 2016 01:34 ET
|
DBV Technologies
MONTROUGE, France, July 5, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today...
DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Mailys Ferrere
June 21, 2016 16:32 ET
|
DBV Technologies
Montrouge, France, June 21, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today...
DBV Technologies: Late-Breaking Presentation at EAACI Highlights Viaskin(r) Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression
June 15, 2016 16:34 ET
|
DBV Technologies
Early-Stage Proprietary Model Suggests that Serum Biomarkers may help Monitor Treatment Progression with Viaskin Peanut
Additionally, Another DBV Data Presentation is Chosen as "Best of Poster...
DBV Technologies Announces Publication of Preclinical Data in JACI Suggesting EPIT(r) Provides Sustained Protection Against Anaphylaxis
June 13, 2016 01:36 ET
|
DBV Technologies
DBV Technologies Announces Publication of Preclinical Data in JACI Suggesting EPIT® Provides Sustained Protection Against Anaphylaxis
MONTROUGE, France, June 13, 2016 (GLOBE NEWSWIRE)...
DBV Technologies and Nestle Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy
May 31, 2016 01:06 ET
|
DBV Technologies
BAGNEUX, France, May 31, 2016 (GLOBE NEWSWIRE) --
DBV Technologies and Nestlé Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk...
DBV Technologies Announces Filing of 2015 "Document de Reference" and 2015 Annual Report on Form 20-F
April 28, 2016 17:34 ET
|
DBV Technologies
MONTROUGE, France, April 28, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today...
DBV Technologies Announces Presentation from NIAID-sponsored CoFAR6 Phase II Trial Reaffirming Viaskin(R) Peanut Safety and Efficacy
March 04, 2016 13:41 ET
|
DBV Technologies
Results Presented at the AAAAI Meeting Showed CoFAR6 Met Primary Endpoint, With a Strong Response Observed in Children
Early Mechanistic Results are In-Line with DBV's Preclinical...
DBV Technologies Announces Publication of Phase Ib Trial Results in the Journal of Allergy and Clinical Immunology (JACI) Supporting Safety and Tolerability of Viaskin(R) Peanut
February 25, 2016 16:56 ET
|
DBV Technologies
MONTROUGE, France, Feb. 25, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today...
DBV Technologies: First Experimental Results for the Treatment of Colitis with Viaskin(r) will be presented at the Crohn's & Colitis Foundation of America's 2015 Advances in IBD Conference (AIBD)
December 10, 2015 01:36 ET
|
DBV Technologies
BAGNEUX, France, Dec. 10, 2015 (GLOBE NEWSWIRE) -- First Experimental Results for the Treatment of Colitis with Viaskin® will be presented at the Crohn's & Colitis Foundation of America's...
DBV Technologies Announces Initiation of Phase III Study of Viaskin(r) Peanut for the Treatment of Peanut Allergic Children
December 07, 2015 17:05 ET
|
DBV Technologies
BAGNEUX, France, Dec. 7, 2015 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today...